SCHEMBL4416569

SCHEMBL4416569

CCCOC(=O)N1CCC(OCc2nc(-c3ccc(S(C)(=O)=O)cc3)no2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 9/20 0.57
LMNA P02545 3/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
HTT P42858 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.45
CHRM2 P08172 1/20 0.42
CHRM1 P11229 1/20 0.42
EPHX1 P07099 1/20 0.41
EPHX2 P34913 1/20 0.41
KCNH2 Q12809 1/20 0.41
DPP4 P27487 1/20 0.41
DPP7 Q9UHL4 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4414426 0.89 GPR119 (0.56) GPR119LMNAMAPK1SMN1; SMN2HTT
SCHEMBL388084 0.87 GPR119 (0.75) GPR119LMNAMAPK1SMN1; SMN2HTT
SCHEMBL4420442 0.86 GPR119 (0.77) GPR119
SCHEMBL4424816 0.86 GPR119 (0.58) GPR119SMN1; SMN2DPP4DPP7ALDH1A1
SCHEMBL4419176 0.84 GPR119 (0.43) GPR119SMN1; SMN2CHRM2CHRM1
SCHEMBL4426169 0.83 GPR119 (0.57) GPR119LMNAMAPK1SMN1; SMN2CYP2C9
SCHEMBL386858 0.82 GPR119 (0.72) GPR119LMNAMAPK1SMN1; SMN2HTT
SCHEMBL391234 0.81 GPR119 (0.71) GPR119LMNAMAPK1SMN1; SMN2HTT
SCHEMBL386509 0.80 GPR119 (0.70) GPR119LMNAMAPK1SMN1; SMN2HTT
SCHEMBL389587 0.80 GPR119 (0.79) GPR119LMNAMAPK1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
WO-2007003960-A1 GPCR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 GPR119 1/4885LMNA 4210/4885MAPK1 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.